Authors' Reply to Tsivgoulis et al.: "Oral Disease-Modifying Treatments for Relapsing Multiple Sclerosis: A likelihood to Achieve No Evidence of Disease Activity or Harm Analysis".
- Published in:
- 2019
- By:
- Publication type:
- Letter
Works matching IS 11727047 AND DT 2019 AND VI 33 AND IP 3
Results: 10
1
2
Comment on: "Oral Disease-Modifying Treatments for Relapsing Multiple Sclerosis: A Likelihood to Achieve No Evidence of Disease Activity or Harm Analysis".
- Published in:
- 2019
- By:
- Publication type:
- Letter
3
A Close Look at BACE1 Inhibitors for Alzheimer's Disease Treatment.
- Published in:
- 2019
- By:
- Publication type:
- journal article
4
Treatment Strategies for Clozapine-Induced Sialorrhea: A Systematic Review and Meta-analysis.
- Published in:
- 2019
- By:
- Publication type:
- journal article
5
A Preliminary Study Evaluating the Safety and Efficacy of Bumetanide, an NKCC1 Inhibitor, in Patients with Drug-Resistant Epilepsy.
- Published in:
- 2019
- By:
- Publication type:
- journal article
6
Efficacy and Safety of Valproic Acid for Spinal Muscular Atrophy: A Systematic Review and Meta-Analysis.
- Published in:
- 2019
- By:
- Publication type:
- journal article
7
Pharmacotherapy of Postpartum Depression: Current Approaches and Novel Drug Development.
- Published in:
- 2019
- By:
- Publication type:
- journal article
8
Correction to: Quantitative Pharmaco-Electroencephalography in Antiepileptic Drug Research.
- Published in:
- 2019
- By:
- Publication type:
- corrected article
9
Treatment of Juvenile Myoclonic Epilepsy in Patients of Child-Bearing Potential.
- Published in:
- 2019
- By:
- Publication type:
- journal article
10
Neuroprotective Actions of Glucagon-Like Peptide-1 (GLP-1) Analogues in Alzheimer's and Parkinson's Diseases.
- Published in:
- 2019
- By:
- Publication type:
- journal article